Mark R Green Selected Research

Mark R Green Research Topics

Disease

37	Neoplasms (Cancer) 09/2010 - 01/2002
28	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2016 - 01/2002
27	Leukemia 09/2010 - 01/2002
15	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2013 - 02/2002
6	Neutropenia 01/2013 - 06/2004
6	Mesothelioma 04/2008 - 03/2002
5	Malignant Mesothelioma 06/2005 - 03/2002
4	Weight Loss (Weight Reduction) 09/2010 - 01/2006
3	Pancreatic Neoplasms (Pancreatic Cancer) 04/2014 - 03/2002
3	Esophagitis 01/2013 - 10/2002
3	Thrombocytopenia (Thrombopenia) 11/2011 - 10/2002
2	Fatigue 11/2011 - 07/2007
2	Diarrhea 11/2011 - 05/2002
2	Anemia 11/2011 - 07/2007
2	Neoplasm Metastasis (Metastasis) 08/2009 - 11/2003
2	Febrile Neutropenia 10/2008 - 07/2007
2	Carcinoma (Carcinomatosis) 05/2003 - 01/2002
1	Adenocarcinoma 04/2014
1	Dehydration (Water Stress) 01/2013
1	Hypertension (High Blood Pressure) 11/2011
1	Infections 11/2011
1	Thrombosis (Thrombus) 11/2011
1	Nausea 11/2011
1	Pneumonia (Pneumonitis) 11/2011
1	Heart Failure 11/2011
1	Stroke (Strokes) 11/2011
1	Lung Neoplasms (Lung Cancer) 12/2007
1	Deglutition Disorders (Dysphagia) 07/2007
1	Dyspnea (Shortness of Breath) 05/2007
1	Disease Progression 03/2005
1	Hyperglycemia 05/2003
1	Cytopenia 10/2002
1	Agranulocytosis (Granulocytopenia) 10/2002

Drug/Important Bio-Agent (IBA)

16	Paclitaxel (Taxol)FDA LinkGeneric 09/2016 - 02/2002
13	Cisplatin (Platino)FDA LinkGeneric 01/2013 - 01/2002
12	Carboplatin (JM8)FDA LinkGeneric 09/2016 - 11/2002
8	Etoposide (VP 16)FDA LinkGeneric 01/2013 - 06/2004
7	PlatinumIBA 09/2016 - 01/2002
7	Irinotecan (Camptosar)FDA LinkGeneric 01/2013 - 03/2002
6	Gemcitabine FDA Link 04/2014 - 03/2002
4	Bevacizumab (Avastin)FDA Link 09/2016 - 01/2006
4	Pemetrexed (MTA)FDA Link 10/2013 - 03/2002
4	Topotecan (Hycamtin)FDA LinkGeneric 12/2007 - 02/2002
3	Docetaxel (Taxotere)FDA Link 04/2014 - 06/2002
3	Vinorelbine (Navelbine)FDA LinkGeneric 12/2007 - 10/2002
2	Capecitabine (Xeloda)FDA Link 04/2014 - 05/2004
2	Hemoglobins (Hemoglobin)IBA 01/2013 - 09/2009
2	ErbB Receptors (EGF Receptor)IBA 09/2010 - 03/2005
2	Gefitinib (Iressa)FDA Link 09/2010 - 03/2005
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 06/2005 - 06/2004
2	thiamine triphosphorate (TTP)IBA 09/2004 - 03/2002
2	Folic Acid AntagonistsIBA 04/2004 - 11/2002
1	ElectrolytesIBA 11/2011
1	Proteins (Proteins, Gene)FDA Link 06/2010
1	MucinsIBA 06/2010
1	sulindac sulfone (exisulind)IBA 02/2009
1	2,2'-dithiodiethanesulfonic acid (dimesna)IBA 10/2008
1	pegfilgrastim (Neulasta)FDA Link 10/2008
1	Darbepoetin alfa (Aranesp)FDA Link 10/2008
1	Capsules (Microcapsules)IBA 07/2008
1	5,6-dihydro-5-azacytidineIBA 04/2008
1	CytidineIBA 04/2008
1	Filgrastim (Neupogen)FDA Link 07/2007
1	Indicators and Reagents (Reagents)IBA 01/2006
1	Drug CombinationsIBA 01/2006
1	cositecanIBA 06/2005
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 03/2005
1	Tamoxifen FDA LinkGeneric 02/2005
1	irofulvenIBA 09/2004
1	Platinum Compounds (Compounds, Platinum)IBA 04/2004
1	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2004
1	AntibodiesIBA 11/2003
1	Keratins (Keratin)IBA 11/2003
1	Coloring Agents (Dyes)IBA 11/2003
1	Glucose (Dextrose)FDA LinkGeneric 05/2003
1	Tumor Biomarkers (Tumor Markers)IBA 03/2002
1	B 9430IBA 02/2002

Therapy/Procedure

20	Therapeutics 09/2016 - 01/2002
14	Drug Therapy (Chemotherapy) 04/2014 - 01/2002
12	Radiotherapy 01/2013 - 09/2002
7	Chemoradiotherapy 09/2010 - 10/2002
6	Induction Chemotherapy 09/2009 - 10/2002
4	Combination Drug Therapy (Combination Chemotherapy) 12/2007 - 03/2002
2	Adjuvant Chemotherapy 06/2010 - 11/2008
1	Conformal Radiotherapy 01/2010
1	Treatment Delay 10/2008
1	Intravenous Infusions 02/2008
1	Salvage Therapy 09/2004